Skip to navigation Skip to main content
Diana Ernst, RPh

Diana Ernst, RPh

Editorial Director https://www.endocrinologyadvisor.com
Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Bone Metabolism

FDA Approves First-in-Class Sclerostin-Inhibitor for Postmenopausal Women at High Risk for Fracture

By
Publish Date

The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapies.

Type 2 Diabetes

Soliqua 100/33 Indication Expanded to Include T2D Patients Uncontrolled on Oral Antidiabetic Agents

By
Publish Date

The Food and Drug Administration (FDA) has approved an expanded indication for Soliqua 100/33 to include use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are uncontrolled on oral antidiabetic agents, in addition to those inadequately controlled on basal insulin or lixisenatide.

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More

Next post in Type 2 Diabetes